Published on December 14, 2017
What is personalized medicine, and how can it help AML (acute myeloid leukemia) patients? Broadcasted live from the 2017 ASH (American Society of Hematology) meeting, Patient Power’s Andrew Schorr was joined by AML experts Dr. Gwen Nichols, Executive Vice President and Chief Medical Officer at The Leukemia & Lymphoma Society (LLS), Dr. Ross Levine, the Laurence Joseph Dineen Chair in Leukemia Research at Memorial Sloan Kettering Cancer Center, and Rick Ross, an AML patient advocate. The expert panel shared an overview of the AML news coming out of ASH, an update on personalized medicine options currently available and highlighted helpful resources for patients and their loved ones.
This is a Patient Empowerment Network program produced by Patient Power, in partnership with The Leukemia & Lymphoma Society (LLS). We thank Astellas, Celgene Corporation, Novartis, Pfizer and Seattle Genetics for their support.